Morgan Stanley
NEUP

Morgan Stanley’s Neuphoria Therapeutics NEUP Stock Holding History

Morgan Stanley’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254 Hold
58
– – ﹤0.01% 7817
2026
Q1 		$236 Hold
58
– – ﹤0.01% 7684
2025
Q4 		$225 Buy
58
+51
+729% +$362 ﹤0.01% 7612
2025
Q3 		$83 Hold
7
– – ﹤0.01% 7720
2025
Q2 		$50 Hold
7
– – ﹤0.01% 7789
2025
Q1 		$40 Hold
7
– – ﹤0.01% 7801
2024
Q4 		$24 Sell
7
-68
-91% -$240 ﹤0.01% 7839
2024
Q3 		$393 Buy
75
+9
+14% +$71 ﹤0.01% 7323
2024
Q2 		$609 Buy
66
+58
+725% +$632 ﹤0.01% 7209
2024
Q1 		$97 Sell
8
-7,906
-100% -$104K ﹤0.01% 7379
2023
Q4 		$141K Buy
+7,914
New +$226K ﹤0.01% 5820

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Morgan Stanley's NEUP Position: Q2 2026 in Review

Morgan Stanley held its Neuphoria Therapeutics (NEUP) position steady in Q2 2026 at 58 shares worth $254. The position accounts for ﹤0.01% of the portfolio, ranked #7817.

Morgan Stanley first reported a position in NEUP in Q4 2023 and has held it in 11 quarters since. The position peaked at $141K in Q4 2023. 22 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

  • Morgan Stanley held 58 shares of Neuphoria Therapeutics worth $254 as of Q2 2026.
  • Morgan Stanley left its Neuphoria Therapeutics share count unchanged in Q2 2026.
  • Neuphoria Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7817 holding.
  • Morgan Stanley first reported a position in Neuphoria Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Morgan Stanley's Neuphoria Therapeutics position peaked at $141K in Q4 2023.
  • 22 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.